BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld

BioWorld

July 5, 2017

View Archived Issues

In the clinic

Zealand Pharma A/S, of Copenhagen, started a multinational phase III trial with dasiglucagon in four countries (Austria, Germany, Canada and the U.S.). Read More

Appointments and advancements

Active Biotech AB, of Lund, Sweden, named Helén Tuvesson CEO. Read More

Other news to note

Steadymed Ltd., of San Ramon, Calif., has submitted an FDA new drug application for its lead candidate, Trevyent (treprostinil), for the treatment of pulmonary arterial hypertension. Read More

Holiday notice

BioWorld's offices were closed in observance of Independence Day in the U.S. Read More

Inactivated bacteria 'Qu' the immune system in immunotherapy effort

If Qu Biologics Inc. CEO Hal Gunn was dismayed at presenting the company's poster in the back of the colossal exhibit hall at Chicago's McCormick Place during Digestive Disease Week (DDW) in May, he didn't complain. Read More

EU seeks to control AMR, issues new guidelines

LONDON – The EU has set out a new plan for tackling antimicrobial resistance (AMR) and delivered the first item on the to-do list in the form of guidelines for adoption by all member states on the prudent use of antimicrobial drugs in humans. Read More

Lack of epigenetic enzyme leaves neurons a TAD disorganized

Changes in the 3-D organization of chromosomes in neurons affected the expression of genes that are important for the formation of neuronal connections and that have been implicated in schizophrenia risk, researchers at the Mount Sinai School of Medicine reported in the July 3, 2017, issue of Nature Genetics. Read More

U.K. CMO: Democratize genomics, add to care for all patients

LONDON – The U.K.'s chief medical officer (CMO) has issued a call to "democratize genomics" and make DNA sequencing an "expected part of care" for all patients with cancer or a rare disease. Read More

Biopharmaceutical patents are once again safe in Canada following Supreme Court ruling

"Promises are not the yardstick against which utility is to be measured," the Supreme Court of Canada said in a unanimous ruling Friday that struck down the so-called Promise Doctrine, a judicial test lower courts have used to invalidate 26 patents covering 22 drugs over the past 12 years. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing